10-K: ABVC BioPharma Reports Zero Revenue, Increased Losses in 2025

ABVC BioPharma, Inc. reported a significant increase in net loss and no revenue for the fiscal year ended December 31, 2025, alongside ongoing clinical trial progress and efforts to address internal control weaknesses.

Summary

• ABVC BioPharma, Inc. is an early-stage biotechnology company focused on developing seven new drugs and one medical device, all licensed from related parties.
• The company reported zero revenue for the year ended December 31, 2025, a 100% decrease from $509,589 in 2024, primarily due to licensees' funding issues and a restatement of previously recognized revenue.
• Net loss for 2025 increased by 59% to $8,376,959, compared to $5,259,037 in 2024.
• Operating expenses rose by 37% to $7,151,259 in 2025 from $5,214,068 in 2024, largely driven by increased stock-based compensation for consulting services and rent.
• A working capital deficit of $3,662,633 was reported as of December 31, 2025, compared to $4,377,646 in 2024.
• Net cash used in operating activities increased by 65% to $2,986,299 in 2025 from $1,809,145 in 2024.
• The company successfully completed Phase II clinical trials for ABV-1504 (Major Depressive Disorder) and Phase II Part 1 for ABV-1505 (Adult Attention-Deficit Hyperactivity Disorder), with interim analysis for Phase II Part 2 of ABV-1505 completed in December 2023.
• A Phase II study for the medical device ABV-1701 (Vitargus in vitrectomy surgery) was initiated in Q2 2023 in Australia and Thailand.
• Material weaknesses in internal control over financial reporting were identified, leading to a restatement of financial statements for the third quarter of 2025 and the full fiscal year 2023.
• Nasdaq listing compliance issues regarding minimum bid price and stockholders' equity were resolved in May 2025.
• The company acquired land in Taoyuan City, Taiwan, from a related party (Shuling Jiang) for $4,656,461, paid in restricted common stock and warrants, with a nominee holding arrangement due to local regulatory restrictions.
• A convertible loan agreement with Rgene was converted in May 2024 (company informed April 2025), increasing ownership to 37% and securing a board seat.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging report, with zero revenue and increased losses, compounded by internal control weaknesses and project delays, despite some clinical progress and financing activities.

Positives

• Successful completion of Phase II clinical study for ABV-1504 (Major Depressive Disorder), meeting the primary endpoint with a significant 13.2-point reduction in MADRS score for the high dose.
• Positive results from Phase II Part 1 clinical trial for ABV-1505 (Adult ADHD), demonstrating safety, tolerability, and efficacy with an 83.3% improvement in ADHD-RS-IV score for the ITT population.
• Initiation of Phase II study for the medical device ABV-1701 (Vitargus) in Australia and Thailand in Q2 2023, with ongoing product improvements.
• Resolution of Nasdaq minimum bid price and stockholders' equity compliance issues in May 2025, maintaining listing on The Nasdaq Capital Market.
• Acquisition of land in Taiwan for future botanical drug raw material cultivation, aiming to improve product quality and lower costs upon commercialization.
• Conversion of the Rgene convertible loan, increasing the company's ownership to 37% and securing a board seat for Dr. Jiang.
• Net cash provided by financing activities increased significantly to $4,637,995 in 2025 from $1,980,769 in 2024, indicating successful capital raising efforts.

Negatives

• Zero revenue reported for the year ended December 31, 2025, a 100% decrease from $509,589 in 2024.
• Significant net loss of $8,376,959 in 2025, representing a 59% increase in loss compared to $5,259,037 in 2024.
• Working capital deficit of $3,662,633 as of December 31, 2025.
• Net cash used in operating activities increased by 65% to $2,986,299 in 2025, indicating a higher cash burn rate.
• Material weaknesses identified in internal control over financial reporting, leading to financial statement restatements for Q3 2025 and FY 2023.
• Several projects, including ABV-1501 (Triple Negative Breast Cancer) Phase II trial in Taiwan and ABV-2002 (Corneal Storage Solution) clinical development, were put on hold due to lack of funding.
• An impairment loss of $803,008 was recognized on the equity investment in BioHopeKing Corporation (BHK) due to deteriorating financial condition.
• Revenue recognition issues leading to restatement, specifically regarding funds from OncoX and ForSeeCon being indirectly sourced from a related party (BioFirst) and not meeting fundraising covenants.
• High stock-based compensation expenses ($4,142,816 in 2025) contributed significantly to operating losses.
• The BioKey GMP manufacturing license expired on December 2, 2024, with renewal in progress, posing a potential operational risk.

Risks

• Unfavorable global economic conditions, including health and safety concerns (e.g., COVID-19 impact), could adversely affect business, financial condition, and results of operations.
• No history in obtaining regulatory approval for, or commercializing, any new drug candidate.
• Growth is dependent on the ability to successfully develop, acquire, or license new drugs, with no assurance of recovering investment.
• Current or future products may have side effects, leading to product liability claims, market withdrawal, or increased marketing costs.
• Conducting clinical trials outside the United States carries risks, including FDA non-acceptance of data, foreign regulatory hurdles, and diminished intellectual property protection.
• Failure of clinical trials to demonstrate safety and efficacy could result in additional costs, delays, or inability to complete development and commercialization.
• Even with marketing approval, products may fail to achieve market acceptance by physicians, patients, and third-party payors.
• Inability to enter or maintain successful collaborations or strategic partnerships could hinder product development and commercialization.
• Licensors may terminate license agreements, abruptly ending research and development of new drug candidates.
• Dependence on a single supplier (Yukiguni) for the API of certain drug candidates (ABV-1703, ABV-1519, ABV-1502, ABV-1501) poses supply chain risks.
• Use of hazardous chemicals and biological materials in research and development could lead to costly claims for improper handling, storage, or disposal.
• Failure to maintain and monitor drug candidate manufacturing facilities in compliance with good manufacturing practice (GMP) standards could contaminate clinical trial results.
• Cybersecurity incidents and decentralization of documents may harm business, damage reputation, and increase costs.
• Pharmaceutical patents and patent applications involve complex legal and factual questions, and intellectual property rights may not be adequately protected or enforced globally.
• Changes in patent law could negatively impact patent positions.
• Inability to protect the confidentiality of trade secrets could harm business and competitive position.
• Third parties may assert that employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.
• Substantial competition from companies with considerably more resources and experience may prevent successful commercialization.
• International operations expose the company to currency exchange and repatriation risks, as well as political and economic instability (e.g., China-Taiwan geo-political tensions).
• Exposure to liabilities under the U.S. Foreign Corrupt Practices Act (FCPA) and Chinese anti-corruption law.
• Reliance on a small number of licensees for a substantial portion of revenue, with risk of termination of agreements.
• Potential scrutiny, criticism, and negative publicity involving U.S.-listed Chinese companies could harm business and stock price.
• Existing indebtedness may adversely affect the ability to obtain additional funds and increase vulnerability to economic downturns.
• Failure to remediate a material weakness in internal accounting controls could result in material misstatements and regulatory scrutiny.
• The board's authority to create new series of preferred stock without shareholder approval could adversely affect common stockholders' rights.
• Inability to secure financing needed for future operating needs on acceptable terms could compromise business plans.
• Volatility of common stock share price, influenced by factors beyond the company's control.
• Insiders might have substantial influence over the company, potentially delaying or preventing changes in corporate control.
• Future sales and issuances of common stock or rights to purchase common stock could result in dilution.
• Common stock may be subject to penny stock rules, making it more difficult for shareholders to sell.
• Failure to meet Nasdaq continued listing requirements could result in delisting.
• Significant increased costs and management time required for public company compliance.

Future Outlook

The company plans to advance ABV-1701 Vitargus to the pivotal trial phase and focus on licensing ABV-1504 for MDD after its successful Phase II completion. It also aims to complete the Phase II, Part 2 clinical trial for ABV-1505 for ADHD. The strategy involves out-licensing drug and medical device candidates to major pharmaceutical companies for Phase III and commercialization. BioFirst is targeting to complete the construction of a GMP factory in Hsinchu Biomedical Science Park, Taiwan, in 2026, which would enable ABVC to manufacture Vitargus with world-class technology.

Management Comments

• "We devote our resources to building a sophisticated biotech company and becoming a pioneer in the biopharmaceutical industry."
• "The Company is working on upgrading the facility and equipment, so the renewal of licenses is in progress."
• "The company is working on improvements to the Vitargus Product through the new batch of investigational product."
• "Managements plan is to continue to improve operations to generate positive cash flows and raise additional capital through private or public offerings, or financial support from related parties or shareholders."
• "To obtain more business opportunities, we have engaged more consultants to explore such opportunities, which increased our net loss in 2025."

Industry Context

StockSavvy.ai notes that ABVC BioPharma operates in the highly competitive and capital-intensive biotechnology industry, characterized by long development cycles and significant regulatory hurdles. The company's focus on botanical drugs aligns with a niche but growing interest in natural-derived therapeutics, potentially offering fewer side effects compared to synthetic alternatives. However, its early-stage pipeline and reliance on out-licensing for commercialization place it at a disadvantage against larger, more established pharmaceutical companies with greater resources and market penetration capabilities. The challenges in securing funding and the need for restatements highlight the operational complexities and financial fragility common among smaller biopharmaceutical firms.

Comparison to Industry Standards

• ABVC BioPharma's zero revenue and substantial net losses in 2025 are significantly below industry standards for companies with products in Phase II development, which often generate some licensing or collaboration revenue.
• The company's working capital deficit of $3.66 million and increased cash outflow from operations indicate a weaker financial position compared to many peers who maintain positive cash flow or robust capital reserves to fund R&D.
• The repeated Nasdaq compliance issues, while resolved, suggest a higher level of financial instability and operational oversight challenges compared to well-capitalized biotech firms like Amgen or Gilead Sciences, which typically maintain strong balance sheets and consistent compliance.
• The reliance on related-party transactions for funding and land acquisition, as well as the restatement of financial statements due to accounting errors, points to corporate governance and financial reporting practices that fall short of best practices seen in leading pharmaceutical companies such as Pfizer or Johnson & Johnson.
• The long development timelines for botanical drugs, while potentially offering unique advantages, also mean a prolonged period without commercial revenue, a common challenge for early-stage biotechs but one that requires exceptional capital management and investor confidence, which ABVC appears to struggle with.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not a party to any material legal or administrative proceedings and is not aware of any pending legal or administrative proceedings against it.

Related Party Transactions

• The company has multiple collaborative agreements with related parties including BioFirst, Rgene, OncoX, ForSeeCon Eye Corporation (FEYE), BioHopeKing Corporation (BHK), AiBtl Holding, Lion Arts Promotion, Inc., Shuling Jiang, and other members of the Jiang family.
• In 2025, the company received $0 revenue from licensing agreements with OncoX and FEYE, compared to $200,000 and $296,000 respectively in 2024.
• Financial statements for Q3 2025 were restated due to inappropriate revenue recognition from OncoX ($560,000) and ForSeeCon ($200,000), as funds were indirectly sourced from BioFirst (a related party) and did not meet fundraising covenant requirements.
• Consulting fees paid to Lion Arts (an entity controlled by the Jiangs) amounted to $219,992 in 2025 and $104,083 in 2024.
• Loans to BioFirst: an outstanding balance of $761,016 as of December 31, 2025, with accrued interest of $212,839. All outstanding principal and interests were collected on February 26, 2026.
• Convertible loan to Rgene: outstanding balance of $0 as of December 31, 2025 (fully converted to Rgene common stock), compared to $500,000 in 2024. The company now owns 37% of Rgene.
• Loans to BioFirst (Australia): outstanding loan balances and allocated research fee of $681,185, with accrued interest of $158,798 as of December 31, 2025. Expected credit losses of $839,983 were recognized in 2023.
• Due from BioHopeKing Corporation (BHK): $120,210 as of December 31, 2025, with expected credit losses of $120,210 recognized in 2024.
• Due to the Jiangs (controlling beneficiary shareholders): $300 as of December 31, 2025, for working capital advances (no interest, due on demand).
• Acquisition of land in Puli Township, Taiwan, by AiBtl (a majority-owned subsidiary) for $7,670,000, paid in AiBtl common stock. A nominee holding agreement was executed with landowners due to foreign ownership restrictions.
• Acquisition of land in Taoyuan City, Taiwan, from Shuling Jiang (a director and >10% shareholder) for $4,656,461, paid in 2,035,136 restricted common shares ($1.65/share) and 1,000,000 warrants ($2.50/share). The company also assumed a $500,000 liability owed on the land. A nominee holding agreement was entered into in February 2026.
• A one-year consulting agreement was entered with Shuling Jiang for land-related services, with compensation of 1,000,000 restricted shares over a 5-year vesting schedule.
• AiBtl issued convertible notes payable to an employee (related party) for $150,000 (repaid in 2025) and two notes totaling $240,000 in December 2025.

Stakeholder Impact

• Shareholders face significant risks due to zero revenue, increased net losses, a working capital deficit, and material weaknesses in internal controls, which could negatively impact share price and investor confidence. There is also a risk of dilution from future equity issuances and stock-based compensation.
• Employees are affected by the company's financial instability, although stock-based compensation is a significant part of remuneration. Management changes and project delays could impact morale and retention.
• Customers and partners may experience delays in clinical trials and product development due to funding issues, potentially affecting future product availability and partnership viability. Revenue recognition issues with partners highlight potential contractual complexities.
• Creditors face risks due to the company's existing indebtedness and working capital deficit, although some loans to related parties were repaid or converted.

Next Steps

• Advance ABV-1701 Vitargus to the pivotal trial phase.
• Focus on licensing ABV-1504 for MDD after Phase II completion.
• Complete Phase II, Part 2 clinical trial for ABV-1505 for ADHD.
• Out-license drug candidates and medical device candidates to major pharmaceutical companies for Phase III and pivotal clinical trials.
• Upgrade BioKey's GMP facility and equipment for license renewal.
• Initiate ABV-1601 Phase II clinical study around the end of 2026.
• Begin Phase II clinical trials of ABV-1702 in Q4 2026.
• Initiate ABV-1703 Phase II trial in 2026 and submit IND to Taiwan FDA thereafter.
• Complete construction of BioFirst's GMP factory in Hsinchu Biomedical Science Park in 2026.
• Hire personnel with requisite technical accounting knowledge to remediate material weaknesses in internal control over financial reporting.
• Negotiate new terms for AiBtl's convertible notes payable that matured in November 2025.
• Finalize the holding structure for the acquired land in Taiwan in accordance with legal and regulatory requirements.
• Shareholders to approve an increase in shares available under the 2016 Equity Incentive Plan at the March 26, 2026 annual meeting.

Key Dates

Recommendation

The company reported zero revenue and a substantial increase in net loss for 2025, alongside a persistent working capital deficit and significant cash burn from operations. The identified material weaknesses in internal controls and the need for financial restatements indicate fundamental operational and governance issues. While there is some progress in clinical trials and financing activities, the overall financial health is precarious, with several projects on hold due to lack of funding and heavy reliance on related-party transactions. These factors present a high level of risk and uncertainty for investors, suggesting a "sell" recommendation until there is clear evidence of sustainable revenue generation, improved financial controls, and a path to profitability.

Keywords

Biotechnology, Biopharma, Drug Development, Clinical Trials, SEC Filing, 10-K, Financial Report, Major Depressive Disorder (MDD), Attention Deficit Hyperactivity Disorder (ADHD), Oncology, Vitrectomy, Medical Device, Botanical Drugs, Nasdaq, Corporate Governance, Risk Factors, Financial Restatement, Capital Raise, Intellectual Property, GMP Manufacturing, Related Party Transactions